Creating a new antibody treatment for high-risk influenza outbreaks
Official title: Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas
Funded at Celdara Medical, LLC · NIH-10865068 · Data updated 2026-11-12
This study is testing a new treatment called CM-PW3, which is a special antibody that could help protect people at high risk from serious flu strains, like H5N1 and H7N9, and it aims to find the best way to deliver this protection and see how long it lasts.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Celdara Medical, LLC NIH-funded |
| Lab location | 1 site (Lebanon, United States) |
| Project start | April 25, 2022 |
| Project end | May 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $998,375 |
| NIH project number | 5R44AI157074-03 |
| Project ID | NIH-10865068 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals in high-risk groups, such as healthcare workers, the elderly, or those with underlying health conditions.
✕Less likely to help
Patients who are not at high risk for severe influenza or who have already been vaccinated against seasonal influenza may not benefit from this research.
What this research studies
This research aims to develop a new monoclonal antibody called CM-PW3 that can provide immediate protection against severe influenza strains, such as H5N1 and H7N9, which pose significant risks to public health. The project will focus on how to effectively deliver this antibody to high-risk populations and assess how long the protection lasts. By targeting individuals who are most vulnerable to severe influenza, this research seeks to prevent widespread infection and serious health consequences during pandemic outbreaks.
Why it matters
Potential benefit: If successful, this research could offer a new preventive treatment that protects high-risk individuals from severe influenza infections.
How similar studies have gone: Previous research has shown promise in developing monoclonal antibodies for influenza, indicating that this approach has potential for success.
Where this research is happening
-
Celdara Medical, LLC
Lebanon, United States Active
Researchers
- Principal investigator: Cooper, Colleen Doyle — Celdara Medical, LLC
- Study coordinator: Cooper, Colleen Doyle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.